Metagenomi, Inc. Common Stock (MGX)の価格はいくらですか

Metagenomi, Inc. Common Stock (MGX)の価格は$1.21です

Metagenomi, Inc. Common Stock (MGX)の時価総額は何ですか

Metagenomi, Inc. Common Stock (MGX)の時価総額は$45.55Mです

Metagenomi, Inc. Common Stock (MGX) の収益

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

年	収益	変化
提供された日付のデータは十分ではありません。

年

収益

変化

提供された日付のデータは十分ではありません。

企業	収益	収益の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	$2.23B	-	US

企業

収益

収益の差

国